Remnant cholesterol targeting challenged: Olezarsen lowers lipids but fails to reduce coronary plaque
Key Questions
What were the key findings of the Olezarsen study on remnant cholesterol?
Olezarsen reduced triglycerides, remnant cholesterol, and ApoB but did not reduce coronary plaque volume. This challenges assumptions that lowering remnant cholesterol directly leads to atherosclerosis regression.
Does this study affect the use of APOC3 inhibitors?
The results temper enthusiasm for APOC3 and ANGPTL3 inhibitors by showing lipid improvements without plaque regression. Remnant cholesterol remains an emerging risk factor with uncertain therapeutic translation.
What does the study imply for targeting remnant cholesterol in clinical practice?
It underscores the need to look beyond lipid numbers alone when assessing treatment benefit. No lipid-lowering trial has yet demonstrated improved outcomes from selective remnant cholesterol reduction as a primary endpoint.
How does Olezarsen perform in severe hypertriglyceridemia?
It reduces triglycerides and acute pancreatitis events in patients with severe hypertriglyceridemia. However, the lack of plaque reduction raises questions about broader cardiovascular benefits.
Are there ongoing questions about remnant cholesterol as a therapeutic target?
Yes, the findings indicate that therapeutic translation remains uncertain despite its status as an emerging risk factor. Further research is needed to clarify its role in atherosclerosis management.
New study (2026) shows Olezarsen (APOC3 inhibitor) reduces triglycerides, remnant cholesterol, and ApoB but does not reduce coronary plaque, challenging the assumption that targeting remnant cholesterol directly translates to atherosclerosis regression. This counterpoint tempers enthusiasm for APOC3/ANGPTL3 inhibitors and underscores need to look beyond lipid numbers. Remnant cholesterol remains an emerging risk factor but therapeutic translation is uncertain.